PALESTRANTES INTERNACIONAIS

GASTROINTESTINAL

Screen-Shot-2017-11-17-at-4.28.23-PM

Dan Aderka

Graduated at the Tel Aviv University, Israel in 1976.

In parallel to the fellowship in Internal Medicine Dr. Aderka was involved in basic research at the Weizmann Institute of Science in the laboratory of Prof. David Wallach, a research which culminated in the patent on an anti-TNF molecule which was further developed into one of the first biologicals ever used in medicine: Enbrel for Rheumatoid arthritis.

The post-doc position of Dr. Aderka was in the laboratory of Prof. Ian Vilcek at the NYU Medical Center. Upon returning from New York, Dr. Aderka continued his dual scientific and medical activities at the Weizmann Institute and at the Tel-Aviv Medical Center, until 1995, when he switched to Oncology.

In 2003, Dr. Aderka founded the Gastrointestinal Cancer Unit at the largest hospital in Israel (Sheba Medical Center) and became the head of this unit. He was elected as the president of the Israeli Gastrointestinal Cancer Group in 2010, and serves as a member of the ESMO Consensus guidelines on colon cancer.

Dr. Aderka has more than 140 medical and scientific publications.

IMG-20171117-WA0012

Fernando Rivera

– Formado em Medicina pela Faculdade de Salamanca e doutorado pela Universidade de Cantabria.
– Chefe do serviço oncológico do Hospital Marqués de Valdecilla em Santander.
– Gerente da Unidade de Pesquisa Clínica do Hospital Marqués de Valdecilla em Santander.
– Coautor de mais de 20 livros.
– Principal Investigador em mais de 70 estudos fases II e III.
– Autor de mais de 130 artigos científicos publicados. Principalmente na área de Tumores Gastrointestinais e de Cabeça e Pescoço.
– Membro da ESMO.

Franco Roviello

Franco Roviello

Education
Graduation cum laude in Medicine and Surgery (MD degree) July 1987     

Postgraduate Training
October 1988-July 1993 – Surgical training in General and Emergency Surgery University of Siena – Nuovo Policlinico, Departments of Surgery – Siena (Italy) Sub-specialty training and certification in Gastrointestinal Oncologic Surgery

Accreditation in General Surgery July 1992

Academic Appointments
October 1991- 2005 – Assistant Professor, Lecturer – General Surgery (Joint academic and clinical appointment)

University of Siena School of Medicine Department of Surgical Oncology, Nuovo Policlinico University Hospital, Siena

October 2005-2013 – Associate Professor, Lecturer – General Surgery   (Joint academic and clinical appointment)

University of Siena School of Medicine, Department of Surgical Oncology,

October 2015 – Full Professor of Surgery, Senior Lecturer – General Surgery.

– Direttore U.O.C. Chirurgia Generale a Indirizzo Oncologico;
– Direttore f.f. DAI Oncologico;
– Direttore Scuola di Specializzazione in Chirurgia Generale Università di Siena;
– Coordinatore Progetto Chirurgia Miniinvasiva e Robotica AOUS;
– Segretario Generale SICO Societa Italiana di Chirurgia Oncologica;
– Associate Editor Upper GI European Journal of Surgical Oncology;

GENITURINÁRIO

andre-pic-robot

Andre Berger

quinn

David Quinn

David Ian Quinn MBBS (Hons. I) PhD FRACP FACP undertook his early training at St. Vincent’s Hospital in Sydney before completing a PhD in Cancer Biology at the Garvan Institute and moving to the United States in 2000. Associate Professor Quinn is currently the Medical Director of the Norris Cancer Hospital and Clinics, Head, Section of Genitourinary Medical Oncology and Associate Professor of Medicine in the Division of Medical Oncology, Keck School of Medicine, University of Southern California. Prior experience includes Directorship of the Clinical Investigation Support Office and Leadership of the Genitourinary Cancer and Developmental Therapeutics Programs for the USC Norris Comprehensive Cancer Center.  He is a medical oncologist with focus in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics.  David Quinn has published more than 100 papers, reviews and chapters including recent publications in New England Journal of Medicine, Lancet Oncology, Journal of the National Cancer Institute, Cell Stem Cells and Journal of Clinical Oncology. He is a reviewer for more than 50 peer-reviewed journals, is on the editorial boards of American Journal of Clinical Oncology, cancer.net (American Society of Clinical Oncology), Clinical Genitourinary Cancer, Bladder Cancer  and Annals of Oncology and has been an invited speaker in more than 30 countries. Dr. Quinn is a member of the NCI Renal Cancer Task Force, Co-Chair for Genitourinary Cancer in the California Cancer Consortium and is SWOG organ site chair for advanced prostate cancer. His recent focus is on clinical trials and translation applications at USC and with SWOG and the California Cancer Consortium, where he has been principal investigator on more than 100 clinical trials for locally advanced and castrate-resistant prostate cancer, high grade urothelial cancer, advanced renal cell cancer, refractory germ cell tumors and adrenocortical carcinoma.

Work-photo

Monish Aron

Dr. Monish Aron is an expert in robotic and laparoscopic surgery for malignant and benign conditions of the prostate, kidney, bladder, adrenal gland, and ureter. He trained in urology at some of the premier institutions in India, Australia, and the United States. Dr. Aron completed his fellowship training in advanced robotics and laparoscopy at the Cleveland Clinic, and was recruited to USC in 2009. He has received numerous acclaimed awards including the GB Ong Medal from the Royal College of Surgeons of Edinburgh, as well as several awards for his scientific presentations and surgical videos at the American Urological Association Congress. Dr. Aron has published extensively (>200 publications) and serves as reviewer for 8 leading urologic journals, including editorial board appointments for 3 journals. Dr. Aron has played a pioneering role in the development and refinement of robotic prostate and kidney surgery, single incision laparoscopic surgery, and robotic surgery for bladder cancer. Dr. Aron has been invited to speak at and demonstrate minimally invasive surgical techniques at numerous national and international institutions.

GINECOLOGIA

Magrina_Javier---2010--Hi-Resolution

Javier Magrina

1998 – Present
Head – Division of Gynecologic Oncology, Department of Medical & Surgical Gynecology, Mayo Clinic, Scottsdale, Arizona

07/1998 – Present
Professor of Obstetrics and Gynecology – Mayo Clinic College of Medicine and Science

2015 – Present
Director – Fellowship in Minimally Invasive Gynecologic Surgery, Department of Medical & Surgical Gynecology, Mayo Clinic, Phoenix, Arizona

2015 – Present
Vice President – Minimally Invasive Gynecologic Surgery, Obstetrics & Gynecology, Programs in Arizona, Mayo Clinic, Phoenix, Arizona

MAMA

Evandro_De_Azambuja_no_lanyard-2016

Evandro de Azambuja

Evandro de Azambuja, MD, PhD, is the Head of the Medical Support Team (Academic Promoting Team) located at the Jules Bordet Institute in Brussels, Belgium.

Dr de Azambuja earned his first PhD from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil, in May 2007 and his second PhD from the Université Libre de Bruxelles (U.L.B) in December 2015.

His principal interest in oncology is breast cancer, especially in the adjuvant/neoadjuvant settings. He is deeply involved in the conduct of large phase III trials in breast cancer such as HERA (adjuvant trastuzumab), ALTTO (trastuzumab and/or lapatinib) and APHINITY (trastuzumab with or without pertuzumab) and – in the neoadjuvant setting – the LORELEI trial which tests the efficacy of PI3K inhibition. He is also greatly engaged in studies concerning cancer toxicity of new drugs in oncology as well as in long-term follow-up of patients enrolled in clinical trials with focus in cardiotoxicity. Within the latter context, he was a co-author of guidelines on treatment-related cardiac toxicity by the European Society for Medical Oncology (ESMO) and the European Society of Cardiology (ESC). He was past chair of the survivorship of the Belgian Society of Medical Oncology (BSMO).

Dr. de Azambuja is a member of the ESMO Press and Media Affairs Committee and ESMO Fellowship and Award Committee. He was a member of the ESMO Young Oncologists Committee (YOC). He is also a faculty member of the ESMO Leaders’ Generation Program launched in 2016. He was appointed as a Breast Faculty Member of ESMO in 2017 and a board member of the Belgian Society of Medical Oncology (BSMO) since 2015.

Dr. de Azambuja is also a member of the American Society of Clinical Oncology (ASCO) and the Belgian Society of Medical Oncology (BSMO). He is actively involved in editorial boards of the Journal of Clinical Oncology (JCO), “ESMO Open – Cancer Horizons”, and ESMO Perspective.

He has (co)-authored approximately 150 peer-reviewed articles and 9 book chapters. He has been a member of Education and Scientific Committees of the ESMO, EBCC and ECCO meetings.

hugo

Hugo Marsiglia

Experiencia académica
Junio 2017 – presente Director Máster Internacional en Radioterapia Avanzada Universidad de Los Andes – IAEA – FALP
2015 – presente Profesor Docente Universidad de Los Andes Santiago de Chile. Nominación consejo Facultad de medicina 5/8/2015
2000 – presente Director de las jornadas conjuntas Hospital Ramón y Cajal – Instituto Gustave Roussy. Madrid España.
2008 – 2012 – Director del Master International de tecnologías avanzadas en Oncología Radioterápica. Madrid. España.
2000 – 2012 – Director  de  las  jornadas conjuntas  del  Hospital  Clínico de Barcelona- Instituto Gustave Roussy.  Barcelona España.
2001 – 2010 – Profesor Universitario de medicina, especialidad en Radioterapia y Oncología médica. Universidad de Florencia. Escuela de Medicina, Florencia. Italia Concurso nacional. Decreto 2001 Gazzetta Ufficiale.
2001 – 2002 – Profesor adjunto clínico de especialización en Oncología Radioterápica Universidad de Milán, Italia.
1990 – 1996 – Profesor Asociado de Oncología Radioterápica. Universidad Kremlin Bicetre. Escuela de Medicina, Paris. Francia.

Experiencia Profesional
2014 – Presente Director  Médico  del  Instituto  Oncológico  Fundación Arturo López Pérez (FALP) – Santiago de Chile
2012 – 2014 – Jefe de servicio de la  unidad  de  Radioterapia  de  mama – Institut  Gustave Roussy, Villejuif. Francia.
2008 – 2012 – Director Médico del instituto Madrileño de Oncología. Madrid (España)
2001 – 2008 – Jefe de servicio de la  unidad  de  Radioterapia  de  mama – Institut  Gustave Roussy, Villejuif. Francia por concurso nacional.
1997  – 2001 – Co-Director adjunto del Departamento de Oncología Radioterápica. Jefe de servicio de la unidad de Braquiterapia. Instituto Europeo de Oncología, Milán. Italia.
1990 – 1996 – Médico   STAFF   especialista   de   Oncología     Radioterápica.  Institut Gustave Roussy, Villejuif. Francia
1988 – 1990 – Medico  Consultor  de  Oncología Radioterápica.  Hospital  Tenon, Paris, Francia

130624-012-sacchini

Virgilio Sacchini

Virgilio Sacchini, MD is Attending Surgeon, in the Breast Service of Memorial Sloan-Kettering Cancer Center in New York and  Full Professor of Surgery at the Weill Medical College of Cornell University in New York. He was vice-director of the  Breast Department at the European Institute of Oncology in Milan – Italy until September 2000. Dr. Sacchini received his medical degree from the University of Milan Medical School and trained in general surgery at the National Cancer Institute in Milan. In the last 15 years Dr. Sacchini has being involved as co-investigator in several clinical trials in breast cancer. He was Clinical co-ordinator of the Italian Breast Cancer Chemoprevention Study of Tamoxifen. He is participating as clinical investigator in some EORTC (European Organisation for Research and Treatment of Cancer) breast cancer trials.  It is in charge of some clinical trials on breast cancer at MSKCC. He is member at large of the Memorial Sloan Kettering Cancer Center Surgical Protocol Review and past member of the Quality Control and Quality Assurance, data and Safety Monitoring Committee, of Memorial Sloan Kettering Cancer Center. Dr. Sacchini has published more than 180 research papers and  chapter books.

NEURO-ONCOLOGIA

hugo

Hugo Marsiglia

Experiencia académica
Junio 2017 – presente Director Máster Internacional en Radioterapia Avanzada Universidad de Los Andes – IAEA – FALP
2015 – presente Profesor Docente Universidad de Los Andes Santiago de Chile. Nominación consejo Facultad de medicina 5/8/2015
2000 – presente Director de las jornadas conjuntas Hospital Ramón y Cajal – Instituto Gustave Roussy. Madrid España.
2008 – 2012 – Director del Master International de tecnologías avanzadas en Oncología Radioterápica. Madrid. España.
2000 – 2012 – Director  de  las  jornadas conjuntas  del  Hospital  Clínico de Barcelona- Instituto Gustave Roussy.  Barcelona España.
2001 – 2010 – Profesor Universitario de medicina, especialidad en Radioterapia y Oncología médica. Universidad de Florencia. Escuela de Medicina, Florencia. Italia Concurso nacional. Decreto 2001 Gazzetta Ufficiale.
2001 – 2002 – Profesor adjunto clínico de especialización en Oncología Radioterápica Universidad de Milán, Italia.
1990 – 1996 – Profesor Asociado de Oncología Radioterápica. Universidad Kremlin Bicetre. Escuela de Medicina, Paris. Francia.

Experiencia Profesional
2014 – Presente Director  Médico  del  Instituto  Oncológico  Fundación Arturo López Pérez (FALP) – Santiago de Chile
2012 – 2014 – Jefe de servicio de la  unidad  de  Radioterapia  de  mama – Institut  Gustave Roussy, Villejuif. Francia.
2008 – 2012 – Director Médico del instituto Madrileño de Oncología. Madrid (España)
2001 – 2008 – Jefe de servicio de la  unidad  de  Radioterapia  de  mama – Institut  Gustave Roussy, Villejuif. Francia por concurso nacional.
1997  – 2001 – Co-Director adjunto del Departamento de Oncología Radioterápica. Jefe de servicio de la unidad de Braquiterapia. Instituto Europeo de Oncología, Milán. Italia.
1990 – 1996 – Médico   STAFF   especialista   de   Oncología     Radioterápica.  Institut Gustave Roussy, Villejuif. Francia
1988 – 1990 – Medico  Consultor  de  Oncología Radioterápica.  Hospital  Tenon, Paris, Francia

PESQUISA CLÍNICA

BenSolomon_photo

Ben Solomon

Professor Ben Solomon MBBS, PhD, FRACP
Professor Ben Solomon is a medical oncologist at the Peter MacCallum Cancer Centre and Professor of Medicine at the University of Melbourne, Australia. Following a postdoctoral fellowship at the University of Colorado he returned to Peter MacCallum Cancer Centre in 2006 where he practices as a medical oncologist with a focus on clinical and translational research in lung cancer and phase I studies of novel anti-cancer therapies. He has been involved in the clinical development of targeted therapies in lung cancer, including the phase I through to phase III clinical trials with crizotinib that led to its approval in the treatment of ALK-rearranged NSCLC. He continues to be involvement in the development of novel ALK inhibitors and other novel targeted therapies and immunotherapies in NSCLC.

Jill_Brown2

Jill Hagenkord

Dr. Hagenkord is a board-certified pathologist with subspecialty boards in molecular genetic pathology. As Chief Medical Officer, Jill is involved in health product strategy, identification and evaluation of strategic business partnerships, regulatory strategy, health information review, and the development of provider and patient support tools. She also serves as the company liaison to medical professional societies as an active member in the Association for Molecular Pathology, the College of American Pathologists, American College of Medical Genetics and Genomics, and the National Academies of Science, Engineering, and Medicine’s Roundtable on Genomics and Precision Health. Jill received her M.D. from Stanford University School of Medicine in 1999, did residency training at the University of California at San Francisco and the University of Iowa, and completed fellowships at the University of Pittsburgh Medical Center. Subsequently, Dr. Hagenkord practiced pathology at Creighton University Medical Center where she founded iKaryo Diagnostics. Prior to joining Color, Jill was the Chief Medical Officer at 23andMe, Invitae, and Complete Genomics.

ROBÓTICA GENITURINÁRIO

andre-pic-robot

Andre Berger

Work-photo

Monish Aron

Dr. Monish Aron is an expert in robotic and laparoscopic surgery for malignant and benign conditions of the prostate, kidney, bladder, adrenal gland, and ureter. He trained in urology at some of the premier institutions in India, Australia, and the United States. Dr. Aron completed his fellowship training in advanced robotics and laparoscopy at the Cleveland Clinic, and was recruited to USC in 2009. He has received numerous acclaimed awards including the GB Ong Medal from the Royal College of Surgeons of Edinburgh, as well as several awards for his scientific presentations and surgical videos at the American Urological Association Congress. Dr. Aron has published extensively (>200 publications) and serves as reviewer for 8 leading urologic journals, including editorial board appointments for 3 journals. Dr. Aron has played a pioneering role in the development and refinement of robotic prostate and kidney surgery, single incision laparoscopic surgery, and robotic surgery for bladder cancer. Dr. Aron has been invited to speak at and demonstrate minimally invasive surgical techniques at numerous national and international institutions.

TÓRAX

BenSolomon_photo

Ben Solomon

Professor Ben Solomon MBBS, PhD, FRACP
Professor Ben Solomon is a medical oncologist at the Peter MacCallum Cancer Centre and Professor of Medicine at the University of Melbourne, Australia. Following a postdoctoral fellowship at the University of Colorado he returned to Peter MacCallum Cancer Centre in 2006 where he practices as a medical oncologist with a focus on clinical and translational research in lung cancer and phase I studies of novel anti-cancer therapies. He has been involved in the clinical development of targeted therapies in lung cancer, including the phase I through to phase III clinical trials with crizotinib that led to its approval in the treatment of ALK-rearranged NSCLC. He continues to be involvement in the development of novel ALK inhibitors and other novel targeted therapies and immunotherapies in NSCLC.

Gilberto-Lopes

Gilberto Lopes

Gilberto de Lima Lopes Junior, MD, MBA, FAMS
Associate Professor of Clinical Medicine
Medical Director for International Programs
Associate Director for Global Oncology
Co-Leader, Lung Cancer Site Disease Group
Sylvester Comprehensive Cancer Center at the
University of Miami and the Miller School of Medicine

Gilberto Lopes, a medical oncologist, is the medical director for international programs and associate director for Global Oncology at the University of Miami Sylvester Comprehensive Cancer Center and associate professor at the Miller School of Medicine; and associate editor for ASCO University and for the society’s Journal of Global Oncology; he previously worked at the Johns Hopkins University.

Dr. Lopes has published more than 100 papers in journals such as the Journal of Clinical Oncology, Cancer, Nature Reviews, Lancet, Lancet Oncology and Health Affairs. In addition to delivering lectures around the world, he has been principal, co-Principal Investigator or steering committee member in more than 100 studies and clinical trials covering breast, gastrointestinal, genitourinary and thoracic cancers. His other main areas of research interest are health economics, value, policy and access to cancer drugs and treatment in low and middle income countries.

Dr. Lopes is currently a committee member for the International Association for the Study of Lung Cancer (IASLC), a member of the European Society of Medical Oncology expensive, innovative Medicines working group and the chair for the international clinical trials workshop working group and track leader for global health at the American Society of Clinical Oncology (ASCO), as well as an executive board member for the Latin American Cooperative Oncology Group (LACOG).

He has also served as an expert for the International Atomic Energy Agency, the World Health Organization and the Pan-American Health Organization and advised governments, professional societies and industry on issues related to cancer control and treatment in low- and middle-income countries.

SESSÃO ESPECIAL: CARDIO-ONCOLOGIA

daniela-cardinale

Daniela Cardinale

Education and PHD/Masters/Courses
Medicine Degree, University of Milan; specialization in Cardiology, University of Milan (with honours). PhD in Cardiovascular Physiopathology, University of Milan.

Titles
1987-1990: Internal Physician, Coronary Unit, Monzino Cardiology Centre, I.R.C.C.S, Milan
1990-1994: Consultant Cardiologist, Cardiology Division, S. Raffaele Hospital, I.R.C.C.S, Milan
1995-2001: Assistant Cardiologist, Cardiology Unit, European Institute of Oncology, I.R.C.C.S., Milan
2002-2004: Vice Director, Cardiology Unit, European Institute of Oncology, I.R.C.C.S, Milan
2005-2010: Senior Vice Director, Cardiology Unit, European Institute of Oncology, I.R.C.C.S., Milan
2011: Director, Cardioncology Unit, Division of Cardiology, European Institute of Oncology, Milan

Main fields of scientific interest
Cardio-toxicity caused by chemotherapeutics, Prevention and Treatment; Prevention and treatment of post-surgery atrial fibrillation

Publications
Author of more than 100 publications on national and international journals and reviser for the following scientific journals: Journal of American College of Cardiology, Heart, European Journal of Echocardiography, International Journal of Cardiology, Drug Safety, Haematologica, Journal of Chemotherapy, Italian Heart Journal.

Congresses and Teaching
Speaker at national and international conferences. Teacher at courses and seminars of the Italian Association of Hospital Cardiologists, of the Italian Society of Cardiology, of the Cardiovascular Clinical Biochemistry Study Group, of the School of Specialization in Cardiology of the University of Milan, of the Institute of Clinical Physiology of the C.N.R., of the Italian Society of Cardiovascular Echography, of the Italian Association of Medical Oncology, and of  the Italian Society of Haematology.

SESSÃO ESPECIAL: DOR E CUIDADO PALIATIVO

000

Daniel Przybysz

Dr. Przybysz MD is a Radiation Oncology Fellow at the Siteman Cancer Center / Washington University in St. Louis. He is also a Reviewer for the American Society of Radiation Oncology’ (ASTRO) Journals (i.e. Red Journal, PRO, Adv. RO) and for UpToDate.
Dr. Przybysz earned his Medical Degree from the Federal University of Parana (UFPR) conjointly with Harvard Medical School. Following his medical graduation, he did a Gynecology/Oncology Internship at the Massachusetts General Hospital as well as an Oncology Critical Care Internship at the MD Anderson Cancer Center.

Dr. Przybysz did his Radiation Oncology training at the National Cancer Institute of Brazil (INCA) with abroad rotations including the Washington University in St. Louis and The Royal Marsden Hospital in London, UK.

Dr. Przybysz has published more than 15 Clinical Research papers. Lung Cancer, IGRT, Proton Therapy and Adaptive Radiation Therapy are among his major topics.

Dr. Przybysz is currently a member of the American Society of Radiation Oncology (ASTRO), the Brazilian Society for Radiation Therapy (SBRT), the International Association for the Study of Lung Cancer (IASLC), the American Society of Clinical Oncology (ASCO) and the Radiology Society of North America (RSNA).

Presently, he is involved in Clinical Research projects regarding Lung SBRT and Adaptive Lung Radiation Therapy, Protons Hypo-Fractionation, GU and GI Adaptive Radiation Therapy. He leads the Lung Immunotherapy and Radiation Therapy Study Group at his institution.

He has been awarded with Harvard Medical School Phillip Vincent Award and has been recognized as a Leading Physician of The World by the International Association of Healthcare Professionals (IAHCP).

III SIMPÓSIO MULTIDISCIPLINAR

Gilberto-Lopes

Gilberto Lopes

Gilberto de Lima Lopes Junior, MD, MBA, FAMS
Associate Professor of Clinical Medicine
Medical Director for International Programs
Associate Director for Global Oncology
Co-Leader, Lung Cancer Site Disease Group
Sylvester Comprehensive Cancer Center at the
University of Miami and the Miller School of Medicine

Gilberto Lopes, a medical oncologist, is the medical director for international programs and associate director for Global Oncology at the University of Miami Sylvester Comprehensive Cancer Center and associate professor at the Miller School of Medicine; and associate editor for ASCO University and for the society’s Journal of Global Oncology; he previously worked at the Johns Hopkins University.

Dr. Lopes has published more than 100 papers in journals such as the Journal of Clinical Oncology, Cancer, Nature Reviews, Lancet, Lancet Oncology and Health Affairs. In addition to delivering lectures around the world, he has been principal, co-Principal Investigator or steering committee member in more than 100 studies and clinical trials covering breast, gastrointestinal, genitourinary and thoracic cancers. His other main areas of research interest are health economics, value, policy and access to cancer drugs and treatment in low and middle income countries.

Dr. Lopes is currently a committee member for the International Association for the Study of Lung Cancer (IASLC), a member of the European Society of Medical Oncology expensive, innovative Medicines working group and the chair for the international clinical trials workshop working group and track leader for global health at the American Society of Clinical Oncology (ASCO), as well as an executive board member for the Latin American Cooperative Oncology Group (LACOG).

He has also served as an expert for the International Atomic Energy Agency, the World Health Organization and the Pan-American Health Organization and advised governments, professional societies and industry on issues related to cancer control and treatment in low- and middle-income countries.